Abstract
Two discoveries have been crucial for the development of modern immunotherapy to human neoplasia. The first is the technology to produce recombinant proteins in large quantities, pioneered in the late 1970s, that has introduced recombinant cytokines as well as chimeric and humanized antibodies into the clinic. The second is the recognition of short peptides derived from intracellular proteins, which are carried to the cell surface on HLA molecules and present to T lymphocytes a sample of the intracellular protein pool for inspection, which provides the foundation for modern tumor vaccines. In this short review, the principles of and the results with cytokine treatment and vaccines in human neoplasms other than renal cancer are summarized.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Keilholz U, Conradt C, Legha S, Khayat D, Scheibenbogen C, Thatcher N et al. (1998) Results of IL-2-based treatment in advanced melanoma: a case-record based analysis of 631 patients. J Clin Oncol 16:2921–2929
Atkins MB, Lotze MT, Dutcher JP et al. (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–116
Keilholz U, Martus P, Punt CJA et al. (2002) Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomized EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin Eur J Cancer 38:1501–11
Keilholz U, CJA Punt, M Göre, W Kruit, P Patel, D Lienard et al. (2000) Dacarbazine, cisplatin and IFN-α with or without IL-2 in advanced melanoma (EORTC trial 18951). Ann Oncol 11 [Suppl 4]:4
Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R et al. (2001) Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer 84:1036–42
Rosenberg SA, Yang JC, Schwartzentruber DJ et al. (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 4:321–327
Agarwala SA, Glaspy J, O’Day SJ et al. (2002) Results from a randomized phase 111 study comparing combined treatment with histamine dihidrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 20:125–133
Scheibenbogen C, Nagorsen D, Seliger Bolz U (2002) Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. Int J Cancer 99:403–408
Belli F, Testori A, Rivoltini L et al. (2002) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20:4169–4180
Keilholz U, Weber J, Finke JH et al. (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97–138
Conflict of interest:
No information supplied
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Keilholz, U. Immunotherapy in non-renal carcinomas. Urologe 43 (Suppl 3), 138–140 (2004). https://doi.org/10.1007/s00120-004-0605-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-004-0605-7